Lifeboat Foundation

“The modern people of Basque Country, in northern Spain, are genetically similar to the Iberian Iron Age people with ancestry from the Russian steppe. While people around them mixed with different groups and changed, the Basques held on to their heritage.”

Ancient DNA is uncovering the secrets of the unique populations of what are now Portugal and Spain. Two studies published this week include unexpected findings from the DNA of people who lived thousands of years ago on the Iberian Peninsula.

The rugged peninsula is positioned between North Africa, Europe and the Mediterranean on the westernmost edge of the continent, so the DNA of its ancient population shows how it was affected by migration over time.

Continue reading “DNA reveals that local men were replaced in Iberian gene pool thousands of years ago” »

With the announcement today that Mammoth Biosciences has received the exclusive license from the University of California, Berkeley to the new CRISPR protein Cas14, the company now has the last piece of its diagnostics toolkit in place.

Cas14 is a newly discovered protein from the lab of Jennifer Doudna, a pioneer in gene-editing research and a member of the first research team to identify and unlock the power of CRISPR technology.

Doudna and Mammoth Biosciences co-founder Lucas Harrington were part of the team of researchers to identify the new Cas14 protein, which can identify single-stranded DNA. The journal Science published their findings in October 2018.

Continue reading “Mammoth Biosciences adds the final piece of the CRISPR diagnostics puzzle to its toolkit” »

Chinese doctors have reported success with a new type of immunotherapy for multiple myeloma, a blood cancer: 33 out of 35 patients in a clinical trial had clinical remission within two months.

The researchers used a type of T cell called “chimeric antigen receptor (CAR) T.” In a phase I clinical trial in China, the patient’s own T cells were collected, genetically reprogrammed in a lab, and injected back into the patient. The reprogramming involved inserting an artificially designed gene into the T-cell genome, which helped the genetically reprogrammed cells find and destroy cancer cells throughout the body.

Continue reading “33 blood-cancer patients have dramatic clinical remission with new T-cell therapy” »

Researchers are alarmed by “rogue human experimentation” using CRISPR in China.

NEW YORK (AP) — Somewhere in the Midwest, a restaurant is frying foods with oil made from gene-edited soybeans. That’s according to the company making the oil, which says it’s the first commercial use of a gene-edited food in the U.S.

Calyxt said it can’t reveal its first customer for competitive reasons, but CEO Jim Blome said the oil is “in use and being eaten.”

The Minnesota-based company is hoping the announcement will encourage the food industry’s interest in the oil, which it says has no trans fats and a longer shelf life than other soybean oils. Whether demand builds remains to be seen, but the oil’s transition into the food supply signals gene editing’s potential to alter foods without the controversy of conventional GMOs, or genetically modified organisms.

Dr. Barzilai is a chaired Professor of Medicine and Genetics and Director of the biggest Center in the world to study the Biology of Aging.

“Nir is our keynote speaker this year because, quite honestly, if I’d only given him half an hour there is no way he could do justice to his role in our movement. His scientific contributions have been world-leading for decades, but in recent years he has done so much more: he has taken a prominent role in two important rejuvenation startups, and he has also employed his exceptional political skills in forging invaluable new understandings between the biomedical gerontology and regulatory communities. Plus, he’s almost as entertaining a speaker as me!”, says Aubrey de Grey.

The APOE gene, or the “forgetting gene,” has been proven to influence Alzheimer’s risk. So a team of scientists is exploring the effect of gene therapy on people with the riskiest version of the gene.

If it works, the pay-off could be huge.

Gene therapy involves transplanting specific genetic material into human cells in order to correct genetic problems, and is typically attempted on diseases with a singular cause. Alzheimer’s doesn’t seem to have one singular cause — but since the risk of developing it is so strongly associated with the APOE gene, it’s certainly worth a try.

Chimeric antigen receptor–T cell therapy—already approved for some cancers—might help human patients with the autoimmune disorder.